ATK-0102:
557,
582
Wasik, AM; Gandy, MN; McIldowie, M; Holder, MJ; Chamba, A; Challa, A; Lewis, KD; Young, SP; Scheel-Toellner, D; Dyer, MJ; Barnes, NM; Piggott, MJ; Gordon, J. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death. Invest. New Drugs, 1 Aug 2012, 30 (4), 1471-1483. 575 kB. https://doi.org/10.1007/s10637-011-9730-5 #2
Gandy, MN; Mclldowie, M; Lewis, K; Wasik, AM; Salomonczyk, D; Wagg, K; Millar, ZA; Tindiglia, D; Huot, P; Johnston, T; Thiele, S; Nguyen, B; Barnes, NM; Brotchie, JM; Martin-Iverson, MT. Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt’s lymphoma cytotoxicity. Med. Chem. Commun., 1 Oct 2010, 1 (4), 287–293. 177 kB. https://doi.org/10.1039/c0md00108b #11f
N-Ethyl-α-propyl-3,4-methylenedioxyphenethylamine · ETHYL-K
N-Butyl-3,4-methylenedioxyamphetamine · N-Butyl-MDA · MDBU
N-Isobutyl-3,4-methylenedioxyamphetamine · MDIB
N-tert-Butyl-3,4-methylenedioxyamphetamine · MDTB
METHYL-L · α-Bu-N-Me-MDPEA · α-Butyl-N-methyl-3,4-methylenedioxyphenethylamine
N-Methyl-N-propyl-3,4-methylenedioxyamphetamine · MDMPA
N-Methyl-N-isopropyl-3,4-methylenedioxyamphetamine · MDMIPA
PBDB · α-Ethyl-N-propyl-3,4-methylenedioxyphenethylamine
IPBDB · α-Ethyl-N-isopropyl-3,4-methylenedioxyphenethylamine
4,7-Dimethoxy-6-methyl-2-(dimethylamino)indane · N,N-Me-DOMAI
α-Al-N-Me-2,6-DMPEA · α-Allyl-N-methyl-2,6-dimethoxyphenethylamine
α-Al-N-Me-3,5-DMPEA · α-Allyl-N-methyl-3,5-dimethoxyphenethylamine
4-Methallyl-3,5-dimethoxyphenethylamine · DMAL
2C-MAL-2 · 4-(1-Methylallyl)-2,5-dimethoxyphenethylamine
2C-CB · 4-Cyclobutyl-2,5-dimethoxyphenethylamine
2C-MAL · 4-Methallyl-2,5-dimethoxyphenethylamine
N-tert-Butyl-3-methoxycathinone